

Research Article

The Role of Fas-FasL Signaling Pathway in Induction of Apoptosis in Patients with Sulfur Mustard-Induced Chronic Bronchiolitis

Gila Pirzad,¹ Mahvash Jafari,² Sasan Tavana,³ Homayoon Sadrayee,⁴ Saeid Ghavami,⁵ Arezoo Shajiei,⁶ and Mostafa Ghanei¹

¹ Chemical Injury Research Center, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran 1956837173, Iran

² Department of Biochemistry, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran 1956837173, Iran

³ Clinical Research and Development Center, Shahid Modarres Hospital, Shahid Beheshti University, Tehran 1991733981, Iran

⁴ Department of Anatomy, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran 14359151371, Iran

⁵ National Training Program in Allergy and Asthma, University of Manitoba, Winnipeg, MB, Canada R3T 2N2

⁶ Biotechnology Center, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran 1956837173, Iran

Correspondence should be addressed to Mostafa Ghanei, mghaneister@gmail.com

Received 11 October 2010; Accepted 16 December 2010

Academic Editor: Robert H. Rice

Copyright © 2010 Gila Pirzad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sulfur mustard (SM) is an alkylating agent that induces apoptosis and necrosis in cells. Fas-Fas ligand (FasL) interaction could induce apoptosis as well. In this study, it was hypothesized that apoptosis might play an important role in the pathogenesis of SM-induced lung injury via Fas-FasL signaling pathway. In a case-control study, Fas and FasL levels, caspase-3 activity and percent of apoptotic cells were measured in bronchoalveolar lavage (BAL) fluid of patients 20 years after exposure to sulfur mustard and compared with the control group. Results show that Fas and FasL levels were significantly higher in BAL fluid cells in patients group compared with the control ($P = .001$). No significant differences were observed between mild and moderate-severe groups. BAL fluid cells caspase-3 activity was not significantly different among the mild, moderate-severe, and control groups. The data suggest that Fas-FasL-induced apoptosis was impaired in BAL fluid cells of SM-exposed patients which might be one of the initiators of pathogenesis in SM-induced lung injury in these patients.

1. Introduction

Sulfur mustard (SM) is a vesicant compound warfare agent that causes acute and chronic effects on different organs following exposure. It was used against Iranians by Iraqis during Iraq-Iran war. The eyes, the skin, and the respiratory tract are three principal target organs of SM toxicity [1, 2]. A main late pulmonary complication of SM is bronchiolitis obliterans (BOs) [3–5]. However, the mechanism of SM-induced respiratory injuries is not fully understood.

SM is an alkylating agent causing single- and double-strand breaks in the DNA and also reacts with RNA, proteins, and lipid membranes. Thus, it leads to a disordered cell metabolism, causing cell death [6, 7]. In vitro and in vivo studies showed that SM induces time- and dose-dependent apoptosis (physiological cell death) and necrosis (pathological cell death) in cells [8–11].

Two major pathways have been described to trigger apoptosis, namely the extrinsic pathway (death receptor pathway) and the intrinsic pathway (mitochondrial pathway) within the cell. Interestingly, both pathways seem to be involved in SM-induced apoptosis [6, 12]. The extrinsic pathway is activated by ligand-activated death receptors such as Fas ligand- (FasL-) Fas [13]. The binding of Fas-FasL activates caspases, cysteine proteases that recognize aspartate at their substrate cleavage site, and induced apoptosis [14]. SM may develop susceptibility to mutations in tumor suppressor, such as p53, to reduce bcl-2, and to activate caspase-3 in vitro [15].

SM injury to the respiratory system has been related to apoptotic cell death. Several investigators have shown that SM induces apoptosis in lung-derived cells and that the effector caspase-3 is activated in a dose- and time-dependent manner after SM injury [12, 15]. In vivo study with rodent

pulmonary tissue exposed to SM showed increased gene expression of apoptosis-related genes [16]. However, little is known about the signal transduction pathways activated by long-term effects of SM. The purpose of the present study was to investigate the mechanism of cell death via Fas-FasL pathway that occurred in bronchoalveolar lavage (BAL) fluid of patients 20 years after exposure to sulfur mustard. Understanding the molecular and cellular pathways activated in response to SM exposure can lead to therapeutic strategies for prevention or treatment of SM toxicity.

2. Materials and Methods

2.1. Patients Group. Twenty patients with history of exposure to a single high dose of SM from 1985 to 1987 during the Iran-Iraq war who suffered from persistent respiratory and chest discomfort, shortness of breath, cough, and exercise intolerance were reviewed systematically. These patients were selected among all those who were referred to the Emergency Department of Baqiyatallah Hospital as the main referral center for chemically injured patients in Tehran, Iran. The documentation of SM exposure was based on official certification issued by the Iranian Veterans Foundation, which is the official center for compensation of war-disabled victims. Patients with a history of smoking and occupational exposure to toxic agents and having dusty jobs were excluded from the study.

2.2. Control Group. Six healthy volunteers, nonsmoking individuals with no history of SM exposure and no signs or symptoms of respiratory disease were included as the control group. Ethical approval for this research was obtained from the Ethics Committee of the Baqiyatallah University of Medical Sciences, and informed consent was obtained from all patients.

2.3. Pulmonary Function Test (PFT). To assess pulmonary function using spirometry (Hi801 Chest M.I. Spirometer), the residual volume (RV), forced vital capacity (FVC), forced expiratory volume in 1 second (FEV₁), and FEV₁/FVC were measured. Based on postbronchodilator FEV₁, patients were divided into two groups: mild ($n = 10$) and moderate-to-severe ($n = 10$) pulmonary dysfunction [17].

2.4. Bronchoscopy and BAL Sampling. BAL was performed in all subjects using a flexible fiber-optic bronchoscope (Olympus BF1T, Tokyo, Japan). The upper respiratory tract was anesthetized with 2% lidocaine. Atropine (0.75 mg intramuscularly) was administered before the procedure. Supplemental oxygen was given throughout the procedure, and the oxygen saturation was monitored by continuous pulse oxymeter. The bronchoscope was wedged for lavage in the middle lobe segmental bronchus, and four 60-mL aliquots of sterile physiological saline solution warmed to 37°C were infused. The fluid was immediately recovered by gentle suction after each instillation. After that brushing was obtained from each patient via disposable cytology brush (Olympus BC-202D-C10, Tokyo, Japan) in order to increase epithelial

cell number. The cell suspension has been centrifuged at 500 g for 10 minutes in 4°C. Cell plates were washed by cold PBS buffer and were stored in -70°C. For cell sampling, a catheter was introduced via the sampling channel. The sleeve was retracted, and the bristles were exposed. The brush was then rubbed against the epithelial surface under direct visual guidance. The brush was then retracted, and the dissociated cells were well recovered by vortexing the brush in BAL for several seconds; brushing was repeated in three to four locations in the distal trachea and proximal main stem bronchi [18].

2.5. Fas Level Assay. BAL fluid cells Fas level was measured using the RayBio human Fas ELISA kit (Cat NO. ELH-Fas-001, USA). Standards and samples were pipetted into the wells. Presented Fas in samples was bound to the wells by the immobilized antibody. The wells were washed, and biotinylated antihuman Fas antibody was added. After washing away unbound biotinylated antibody, HRP-conjugated streptavidin was pipetted to the wells. The wells were again washed, and a tetramethylbenzidine (TMB) substrate solution was added to the wells and color developed in proportion to the amount of Fas bound. The stop solution has changed the color from blue to yellow, and the intensity of the color was measured at 450 nm.

2.6. Fas Ligand Level Assay. BAL fluid cells FasL level was measured with Fas Ligand “sandwich” ELISA kit (Cat no. QIA27, Oncogene Research Products, USA). Samples and biotinylated detector monoclonal antibody were pipetted into the wells and allowed to incubate for three hours. During this time, presented FasL was bound to the capture and detecting antibodies. Unbound material was washed away, and horseradish peroxidase-conjugated streptavidin was added, which is bound to the detector antibody. The horseradish peroxidase catalyzed the conversion of the chromogenic substrate tetramethylbenzidine (TMB) from a colorless solution to a blue solution (or yellow after the addition of stop reagent). Its intensity was proportional to the amount of FasL protein in the sample. The colored reaction product was quantified using a spectrophotometer by the construction of a standard curve using known concentrations of FasL (provided lyophilized). The concentration of FasL in the sample could be determined by comparing the absorbance obtained from a sample containing an unknown amount of FasL with that standard.

2.7. Caspase-3 Activity Assay. Caspase-3 activity was measured with caspase ELISA kit (Cat no. C2087-12, CPP32, Apotain, Yama, SCA-1, US Biological Company). Briefly, 100 μ L cell lysate or 1 unit recombinant human caspase-3 (positive control) was added to antibody-coated well. The plate was tightly covered and incubated at 37°C for 1 hour. Then, the solutions were removed and after washing 3 times with 150 μ L incubation buffer. Then, 94 μ L incubation buffers, 5 μ L DEVD-AFC, and 1 μ L DTT were added to each well. The plate was tightly covered and incubated at 37°C for 2–4 hours. The samples were read at Ex: 370–425 nm and

TABLE 1: Characteristics of the study populations.

	Control (n = 6)	Mild (n = 10)	Moderate-severe (n = 10)	P value
Sex	Male	Male	Male	—
Age	38.7 ± 6.1	39.5 ± 5.4	43.5 ± 5.3	.12
Height	172.2 ± 3.7	174.5 ± 6.3	168.3 ± 4.5	.42
Weight	74.5 ± 9.8	74.3 ± 10.8	75.4 ± 10.5	.6

Values are shown as mean ± SD.

TABLE 2: The pulmonary function indices of the study populations.

	Control (n = 6)	Mild (n = 10)	Moderate to severe (n = 10)
RV (% predicted)	105.9 ± 9.6	130.2 ± 27.7	160.3 ± 62.5
FVC (% predicted)	88.2 ± 5.9	69.7 ± 18.1*	66.1 ± 13.2*
FEV1 (% predicted)	90.7 ± 6.5	75.3 ± 16.8	58.2 ± 17.6**
FEV1/FVC (%)	88 ± 5.8	87.2 ± 9.3 [#]	65.4 ± 8.7***

Values are shown as mean ± SD. * $P < .05$, ** $P < .01$, and *** $P < .001$ versus control. [#] $P < .001$ versus moderate-severe group.

Em: 490–525 nm in a fluorescence microtiter plate reader. The notable increase in caspase-3 activity was determined by comparing the results with uninduced control.

2.8. Detection of Apoptosis Using Annexin V. To detect phosphatidylserine, annexin V-FITC (Trevigen Inc., Gaithersburg, USA or Boehringer Mannheim, GmbH, Germany) was used in a combination with propidium iodide (PI) using Apopnixin FITC Apoptosis Detection Kit (Katayama Chemical, Osaka, Japan). The FITC-Annexin V fluorescence was read with the FL1 photomultiplier tube, and PI fluorescence was detected using the FL3 channel.

2.9. Protein Concentration Assay. The total protein concentration in BALF was measured by Branford's method³¹ using bovine serum albumin as standard [19].

2.10. Statistical Analysis. SPSS 15.0 (SPSS Inc, Chicago, IL, USA) was used for statistical analysis. Comparisons between the patients and control groups and also between subgroups of patients were assessed by one-way ANOVA. Significant differences between means were analysed by the post-hoc test using Scheffe's F. Spearman's rank correlation coefficient was used to analyse correlations between serum markers. Data was shown as means ± SD. P -values less than .05 were considered statistically significant.

3. Results

3.1. Control and Case Group Demographic Information. Comparison of mean age among the control (38.7 ± 6.1) and patients groups with mild (39.5 ± 5.4) and moderate-to-severe (43.5 ± 5.3) disease did not show significantly different ($P = .24$) (Table 1).

TABLE 3: Differential percentage counts of BAL fluid cells.

	Control (n = 6)	Mild (n = 10)	Moderate to severe (n = 10)
PMN (%)	10.6 ± 1.7	3.8 ± 1.7	18.6 ± 11.3
Lymph (%)	2.5 ± 0.5	2.3 ± 0.8	3.4 ± 1.5
Macrophage (%)	85 ± 21	93.8 ± 2.3	68 ± 21

Values are shown as means ± SD.

3.2. PFT Finding. As described in Table 2, FVC, FEV1 and FEV1/FVC ratio was significantly lower in patients with moderate-to-severe and FVC in patients with mild respiratory disease compared with the control group. FEV1/FVC ratio was significantly higher in patients with mild compared with moderate-to-severe respiratory disease ($P = .001$).

3.3. Differential Cell Count. Differential BAL fluid cell count showed that there was not significant difference in polymorphonuclear (PMN), macrophages, and lymphocytes between the severe and the control group. There was only a difference observed in PMN between the mild and control group. PMN was significantly lower in mild group ($P < .05$) (Table 3).

3.4. BAL Fluid Fas and FasL Levels in the Patient and Control Group. As displayed in Figure 1, the Fas and FasL levels in the BAL fluid cells of patient with mild and moderate-to-severe lung dysfunction are significantly higher than the control group. There were not any significant differences between the mild and moderate-to-severe groups ($P > .05$).

3.5. BAL Fluid Caspase-3 Activity in the Patient and Control Group. BAL fluid cells Caspase-3 activity in the patient and control group is shown in Figure 2. There was not any significant difference in BAL fluid cells caspase-3 activity between the control and patient groups ($P > .05$).

3.6. Percent of Apoptotic and Necrotic Cells in the Patient and Control Group. As seen in Figure 3, there was not any significant difference in percent of apoptotic and necrotic cells of BAL fluid between the control and patient groups. Percent of apoptotic cells is lower than late necrotic cells.

4. Discussion

Apoptosis, programmed cell death, is known to participate in various biological processes such as development, maintenance of tissue homeostasis, and elimination of cancer cells. Malfunctions of apoptosis have been implicated in many forms of human diseases [20, 21]. The potential role of the Fas receptor pathway in asthma has been intensively studied during recent years, albeit with contradictory results. Some studies have demonstrated a decreased expression of Fas receptor or Fas ligand [22] in asthmatic subjects, while other studies have reported an increased expression of Fas receptor and Fas ligand in asthmatic subjects [23]. Several studies showed that SM induces apoptosis by both




FIGURE 1: Fas and FasL levels in the normal, mild and moderate-to-severe patient groups. Values are shown as mean \pm SD. * $P < .05$ versus control.




FIGURE 3: Percent of apoptotic and late necrotic cells of BAL fluid cells in the normal, mild, and moderate-to-severe patient groups. Values are shown as mean \pm SD.




FIGURE 2: Caspase-3 activity in the normal, mild, and moderate-to-severe patient groups. Values are shown as mean \pm SD.

the intrinsic mitochondrial pathway and the extrinsic Fas-Fas ligand pathway [12, 15, 24–27]. In this study, there was significant increase in BAL fluid cells Fas and FasL levels in mild and moderate-to-severe patients compared to the control. FEV1/FVC ratio which is more sensitive for airway obstruction was significantly higher in patients with mild disorder compared with moderate-to-severe respiratory disease. It indicates that the patients with moderate-to-severe symptoms are more prone to airway obstruction.

Our findings are concurrent with previously studies that reported increased Fas and FasL levels in BAL fluid of the patients with BO and acute respiratory distress syndrome compared with their corresponding control group. It has been suggested that it might play important role in pathology of respiratory dysfunction [28–30]. Rosenthal et al. [24] have shown that SM exposure destabilizes intracellular p53 leading to enhanced Fas receptor and FasL expression in human keratinocytes at vesicant SM concentrations. Ray et al. [31], also reported that acute exposure to various mustard concentrations would induces apoptotic pathway in normal human bronchial epithelial cells and small airway epithelial cells via caspase-mediated pathway in vitro. A recent study reported that soluble FasL was increased in serum of SM-exposed patients [32].

Caspases are protease enzymes that play important role in the apoptosis process. Both extrinsic and intrinsic apoptotic pathways activate caspase-3 which is the executioner caspase responsible for the end effects in the apoptosis process [12, 33, 34]. Previous studies showed that caspase activity is involved in the cell death pathway that is induced following exposure to mild concentrations of SM [11, 15, 24, 31, 35]. In present study, there was no difference in BAL fluid cells caspase-3 activity among patient and control groups. Since caspase-3 is considered to be one of

the main effector caspases in apoptotic cell death, it could be concluded that apoptosis was impaired in BAL fluid cells of patient population. Caspase-3 is normally present in the cells in an inactive zymogens form and requires proteolytic processing before they become active. Cleavage is affected by the context of large multiprotein complexes known as DISC (death-inducing signaling complex) and the apoptosome, the formation of which requires several adaptor proteins [33, 34]. It could be assumed that SM exposure might affect apoptosis process by affecting a variety of factors. A second type of regulatory proteins that might be affected in SM-exposed patients could be FLICE inhibitory protein (FLIP). FLIP is able to block early events in Fas and TNF-receptor-like apoptosis-inducing ligand (TRAIL)/TNF family death receptor signaling by precluding caspase-8 recruitment to the DISC. FLIP is a caspase-8-like protein that interferes with caspase-8 binding to the DISC, thus preventing caspase-8 oligomerization and autoactivation [36, 37]. Finally, SM exposure might activate the inhibitor of apoptosis proteins (IAPs), which constitutes a family of evolutionarily conserved apoptotic suppressors. Members of the IAP-family proteins, such as X-linked inhibitor of apoptosis protein (XIAP), have been shown to bind to and inhibit activated caspase-3, -7, and -9 [38].

Therefore, it could be concluded that in SM-exposed patients one of these inhibitory factors might be activated and prevented, the Fas-FasL-induced apoptosis. Patients experienced inhalation injury have developed BO, which was confirmed with pathology and high-resolution CT studies [39, 40]. Besides our clinical data, pathologic finding showed that there was no differences between the low- and high-dose SM exposure after 20 years of initial SM exposure, suggesting that SM effects are not dependant on exposure severity [4]. Lung disease in this group of patients showed a slowly progressive nature. Long-term medical followup after exposure revealed that approximately 75%–80% of our patients experienced mild respiratory impairment and only 20% of them developed severe disease [41]. This finding was conflicting to posttransplant BO which is marked by progressive obstructive lung disease leading to a progressive decline in FEV1 caused by an inflammatory process of the airways identical with chronic allograft rejection [42]. It seems that the major difference is due to the etiology of lung injury, in which over 20 years after exposure most of our patients have shown that their disease has slowly progressive diseasnature, but not experienced without any cure even with different medications. It seems that optimal apoptotic pathway cascades (efferocytosis) are not triggered efficiently. Most in vitro and in vivo studies have planned to investigate cellular damage after a short time of injury, which represents the acute effect and cellular changes [11, 15, 24, 31, 35].

Phosphatidylserine is normally exposed on inner side of plasma membranes, and it becomes exposed on outer membrane surface of the cells undergoing apoptosis. Therefore, annexin V-FITC is able to detect the surface changes in membrane surface that occur early during apoptosis [43]. In this study, further analysis of BAL fluid cells with Annexin V-FITC versus propidium iodide confirmed that the majority of cells became necrotic and only a small

portion became apoptosis. During apoptosis, the cell shrinks, while producing apoptotic bodies which are taken up by neighboring cells by phagocytosis. Very little cytoplasmic material is released into the intercellular space and no or limited inflammation is caused in neighboring tissues. In contrast, during necrosis, the cellular contents are released uncontrolled into the cell's environment which results in damage of surrounding cells and a strong inflammatory response in the corresponding tissue [20, 21]. Based on previous reports, lung diseases are related to inflammatory processes that generate increased reactive oxygen species that correlate with disease severity [44–46]. Additionally, SM upregulates many inflammatory mediators including interleukin- (IL-) 1alpha, IL-1beta, IL-6, IL-8, tumor necrosis factor-alpha (TNF-alpha) and others [47–49]. The main findings of lavage fluid of sulfur mustard-injured patients are inflammation, tissue damage, and neutrophil excess [46]. The neutrophils were shown to produce several cytokines such as tumor necrosis factor and transforming growth factor- β , as an inflammatory factor [50], and express Fas ligand [32, 50]. A study shows that transforming growth factor- β plays a pivotal role in bronchiolitis obliterans pathogenesis [51]. A recent study shows that the level of transforming growth factor- β is significantly increased in lavage fluid of patients with sulfur mustard-exposure, compared with veterans not exposed to sulfur mustard [52]. A 6-month treatment with gamma interferon, an anti-inflammatory effect via down-regulation transforming growth factor- β gene expression, is associated with an improvement in the lung function in sulfur mustard exposed patients with bronchiolitis [53]. However, recent studies showed that the serum levels of inflammatory cytokines such as IL-8, IL-6 [54], IL-1alpha, IL-1beta, and TNF-alpha, except for IL-1Ra and MMP-9 [55], decreased in SM-exposed subjects. More local studies on the lung are needed to clarify the exact role of this cytokines and inflammation.

5. Conclusion

Our study showed that SM exposure inhibited Fas-FasL-induced apoptosis in BAL fluid cells of exposed patients. This inhibition might change PMN, granulocyte and lymphocyte turnover affect cytokine, chemokine, and protein secretion from these cells, and potentiate initiation of lung injury in SM-exposed patients. In future studies, exact mechanism of this inhibition should be addressed for probable therapeutic application. In addition, nonapoptotic importance of Fas-FasL-like macrophage and PMN activation could be investigated.

Acknowledgments

The authors would like to thank the Institute of Rouran and Emam Khomani Hospital for their assistance. This work was supported by a grant from the Chemical Injuries Research Center of Baqiyatallah University of Medical Sciences. Also, It was supported by CIHR/CLA/GSAK and Parker B Francis postdoctoral award in respiratory medicine.

References

- [1] M. Balali-Mood and M. Hefazi, "Comparison of early and late toxic effects of sulfur mustard in Iranian veterans," *Basic and Clinical Pharmacology and Toxicology*, vol. 99, no. 4, pp. 273–282, 2006.
- [2] K. Kehe, H. Thiermann, F. Balszuweit, F. Eyer, D. Steinritz, and T. Zilker, "Acute effects of sulfur mustard injury-Munich experiences," *Toxicology*, vol. 263, no. 1, pp. 3–8, 2009.
- [3] M. Rowell, K. Kehe, F. Balszuweit, and H. Thiermann, "The chronic effects of sulfur mustard exposure," *Toxicology*, vol. 263, no. 1, pp. 9–11, 2009.
- [4] M. Ghanei, H. D. Tazelaar, M. Chilosi et al., "An International collaborative pathologic study of surgical lung biopsies from mustard gas-exposed patients," *Respiratory Medicine*, vol. 102, no. 6, pp. 825–830, 2008.
- [5] M. Ghanei, M. Mokhtari, M. M. Mohammad, and J. Aslani, "Bronchiolitis obliterans following exposure to sulfur mustard: chest high resolution computed tomography," *European Journal of Radiology*, vol. 52, no. 2, pp. 164–169, 2004.
- [6] K. Kehe, F. Balszuweit, D. Steinritz, and H. Thiermann, "Molecular toxicology of sulfur mustard-induced cutaneous inflammation and blistering," *Toxicology*, vol. 263, no. 1, pp. 12–19, 2009.
- [7] B. Papirmeister, A. J. Feister, S. I. Robinson, and R. D. Ford, *Medical Defense Against Mustard Gas*, Toxic Mechanisms and Pharmacological Implications, CRC Press, Boca Raton, Fla, USA, 1991.
- [8] A. Heinrich, F. Balszuweit, H. Thiermann, and K. Kehe, "Rapid simultaneous determination of apoptosis, necrosis, and viability in sulfur mustard exposed HaCaT cell cultures," *Toxicology Letters*, vol. 191, no. 2-3, pp. 260–267, 2009.
- [9] K. Kehe, H. Reisinger, and L. Szinicz, "Sulfur mustard induces apoptosis and necrosis in SCL II cells in vitro," *Journal of Applied Toxicology*, vol. 20, supplement 1, pp. S81–S86, 2000.
- [10] R. K. Kan, C. M. Pleva, T. A. Hamilton, D. R. Anderson, and J. P. Petrali, "Sulfur mustard-induced apoptosis in hairless guinea pig skin," *Toxicologic Pathology*, vol. 31, no. 2, pp. 185–190, 2003.
- [11] D. Steinritz, J. Emmler, M. Hintz et al., "Apoptosis in sulfur mustard treated A549 cell cultures," *Life Sciences*, vol. 80, no. 24-25, pp. 2199–2201, 2007.
- [12] R. Ray, C. M. Simbulan-Rosenthal, B. M. Keyser et al., "Sulfur mustard induces apoptosis in lung epithelial cells via a caspase amplification loop," *Toxicology*, vol. 271, no. 3, pp. 94–99, 2010.
- [13] A. Thorburn, "Death receptor-induced cell killing," *Cellular Signalling*, vol. 16, no. 2, pp. 139–144, 2004.
- [14] S. Kumar, "Regulation of caspase activation in apoptosis: implications in pathogenesis and treatment of disease," *Clinical and Experimental Pharmacology and Physiology*, vol. 26, no. 4, pp. 295–303, 1999.
- [15] D. S. Rosenthal, C. M. G. Simbulan-Rosenthal, S. Iyer et al., "Sulfur mustard induces markers of terminal differentiation and apoptosis in keratinocytes via a Ca²⁺-calmodulin and caspase-dependent pathway," *Journal of Investigative Dermatology*, vol. 111, no. 1, pp. 64–71, 1998.
- [16] J. F. Dillman, C. S. Phillips, L. M. Dorsch et al., "Genomic analysis of rodent pulmonary tissue following bis-(2-chloroethyl) sulfide exposure," *Chemical Research in Toxicology*, vol. 18, no. 1, pp. 28–34, 2005.
- [17] Health America of Pennsylvania, Inc, "Clinical Practice Guidelines Management of COPD," 2008, http://healthamerica.coventryhealthcare.com/web/groups/public/@cvty_regional_chcpa/documents/webcontent/c042490.pdf.
- [18] J. Beheshti, E. J. Mark, H. M. H. Akbaei, J. Aslani, and M. Ghanei, "Mustard lung secrets: long term clinicopathological study following mustard gas exposure," *Pathology Research and Practice*, vol. 202, no. 10, pp. 739–744, 2006.
- [19] M. M. Bradford, "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding," *Analytical Biochemistry*, vol. 72, no. 1-2, pp. 248–254, 1976.
- [20] M. Raff, "Cell suicide for beginners," *Nature*, vol. 396, no. 6707, pp. 119–122, 1998.
- [21] A. Hague and C. Paraskeva, "Apoptosis and disease: a matter of cell fate," *Cell Death and Differentiation*, vol. 11, no. 12, pp. 1366–1372, 2004.
- [22] A. Hamzaoui, K. Hamzaoui, H. Salah, and A. Chabbou, "Lymphocytes apoptosis in patients with acute exacerbation of asthma," *Mediators of Inflammation*, vol. 8, no. 4-5, pp. 237–243, 1999.
- [23] A. Druilhe, B. Wallaert, A. Tsicopoulos et al., "Apoptosis, proliferation, and expression of Bcl-2, Fas, and Fas ligand in bronchial biopsies from asthmatics," *American Journal of Respiratory Cell and Molecular Biology*, vol. 19, no. 5, pp. 747–757, 1998.
- [24] D. S. Rosenthal, A. Veleno, F. P. Chou et al., "Expression of dominant-negative Fas-associated death domain blocks human keratinocyte apoptosis and vesication induced by sulfur mustard," *Journal of Biological Chemistry*, vol. 278, no. 10, pp. 8531–8540, 2003.
- [25] D. S. Rosenthal, C. M. Simbulan-Rosenthal, S. Iyer, W. J. Smith, R. Ray, and M. E. Smulson, "Calmodulin, poly(ADP-ribose)polymerase and p53 are targets for modulating the effects of sulfur mustard," *Journal of Applied Toxicology*, vol. 20, no. 1, pp. S43–S49, 2000.
- [26] K. Kuwano, N. Hagimoto, M. Kawasaki et al., "Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis," *Journal of Clinical Investigation*, vol. 104, no. 1, pp. 13–19, 1999.
- [27] C. M. Simbulan-Rosenthal, R. Ray, B. Benton et al., "Calmodulin mediates sulfur mustard toxicity in human keratinocytes," *Toxicology*, vol. 227, no. 1-2, pp. 21–35, 2006.
- [28] G. Matute-Bello, C. W. Frevert, W. C. Liles et al., "Fas/Fas ligand system mediates epithelial injury, but not pulmonary host defenses, in response to inhaled bacteria," *Infection and Immunity*, vol. 69, no. 9, pp. 5768–5776, 2001.
- [29] G. Matute-Bello, R. K. Winn, M. Jonas, E. Y. Chi, T. R. Martin, and W. C. Liles, "Fas (CD95) induces alveolar epithelial cell apoptosis in vivo: implications for acute pulmonary inflammation," *American Journal of Pathology*, vol. 158, no. 1, pp. 153–161, 2001.
- [30] K. Kuwano, M. Kawasaki, T. Maeyama et al., "Soluble form of Fas and Fas ligand in BAL fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia," *Chest*, vol. 118, no. 2, pp. 451–458, 2000.
- [31] R. Ray, B. Keyser, B. Benton, A. Daher, C. M. Simbulan-Rosenthal, and D. S. Rosenthal, "Sulfur mustard induces apoptosis in cultured normal human airway epithelial cells: evidence of a dominant caspase-8-mediated pathway and differential cellular responses," *Drug and Chemical Toxicology*, vol. 31, no. 1, pp. 137–148, 2008.
- [32] T. Ghazanfari, Z. Sharifnia, R. Yaraee et al., "Serum soluble Fas ligand and nitric oxide in long-term pulmonary complications

- induced by sulfur mustard: sardasht-Iran Cohort Study,” *International Immunopharmacology*, vol. 9, no. 13-14, pp. 1489–1493, 2009.
- [33] I. Budihardjo, H. Oliver, M. Lutter, X. Luo, and X. Wang, “Biochemical pathways of caspase activation during apoptosis,” *Annual Review of Cell and Developmental Biology*, vol. 15, pp. 269–290, 1999.
- [34] A. G. Porter and R. U. Jänicke, “Emerging roles of caspase-3 in apoptosis,” *Cell Death and Differentiation*, vol. 6, no. 2, pp. 99–104, 1999.
- [35] M. A. E. Mol, R. M. van den Berg, and H. P. Benschop, “Involvement of caspases and transmembrane metalloproteases in sulphur mustard-induced microvesicitation in adult human skin in organ culture: directions for therapy,” *Toxicology*, vol. 258, no. 1, pp. 39–46, 2009.
- [36] Y. Kim, N. Suh, M. Sporn, and J. C. Reed, “An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis,” *Journal of Biological Chemistry*, vol. 277, no. 25, pp. 22320–22329, 2002.
- [37] A. Krueger, I. Schmitz, S. Baumann, P. H. Krammer, and S. Kirchhoff, “Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex,” *Journal of Biological Chemistry*, vol. 276, no. 23, pp. 20633–20640, 2001.
- [38] Q. L. Deveraux, N. Roy, H. R. Stennicke et al., “IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases,” *EMBO Journal*, vol. 17, no. 8, pp. 2215–2223, 1998.
- [39] M. Ghanei, M. Mokhtari, M. M. Mohammad, and J. Aslani, “Bronchiolitis obliterans following exposure to sulfur mustard: chest high resolution computed tomography,” *European Journal of Radiology*, vol. 52, no. 2, pp. 164–169, 2004.
- [40] M. Ghanei, H. D. Tazelaar, M. Chilosi et al., “An International collaborative pathologic study of surgical lung biopsies from mustard gas-exposed patients,” *Respiratory Medicine*, vol. 102, no. 6, pp. 825–830, 2008.
- [41] M. Ghanei, J. Aslani, S. Khateri, and K. Hamedanizadeh, “Health status of the civil population of Sardasht 15 years following large—scale wartime exposure to sulfur mustard,” *Journal of Burns and Surgical Wound Care*, vol. 2, article 7, 2003.
- [42] S. G. Gerhardt, J. F. McDyer, R. E. Girgis, J. V. Conte, S. C. Yang, and J. B. Orens, “Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study,” *American Journal of Respiratory and Critical Care Medicine*, vol. 168, no. 1, pp. 121–125, 2003.
- [43] V. A. Fadok, D. R. Voelker, P. A. Campbell, J. J. Cohen, D. L. Bratton, and P. M. Henson, “Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages,” *Journal of Immunology*, vol. 148, no. 7, pp. 2207–2216, 1992.
- [44] M. Jafari and M. Ghanei, “Evaluation of plasma, erythrocytes, and bronchoalveolar lavage fluid antioxidant defense system in sulfur mustard-injured patients,” *Clinical Toxicology*, vol. 57, pp. 1–9, 2010.
- [45] M. Shohrati, M. Ghanei, N. Shampour et al., “Glutathione and malondialdehyde levels in late pulmonary complications of sulfur mustard intoxication,” *Lung*, vol. 188, no. 1, pp. 77–83, 2010.
- [46] A. Emad and G. R. Rcaian, “Immunoglobulins and cellular constituents of the BAL fluid of patients with sulfur mustard gas-induced pulmonary fibrosis,” *Chest*, vol. 115, no. 5, pp. 1346–1351, 1999.
- [47] C. L.K. Sabourin, M. M. Danne, K. L. Buxton, R. P. Casillas, and J. J. Schlager, “Cytokine, chemokine, and matrix metalloproteinase response after sulfur mustard injury to weanling pig skin,” *Journal of Biochemical and Molecular Toxicology*, vol. 16, no. 6, pp. 263–272, 2002.
- [48] T. Anand, R. Vijayaraghavan, I. Bansal, and B. K. Bhattacharya, “Role of inflammatory cytokines and DNA damage repair proteins in sulfur mustard exposed mice liver,” *Toxicology Mechanisms and Methods*, vol. 19, no. 5, pp. 356–362, 2009.
- [49] A. L. Ruff and J. F. Dillman, “Sulfur mustard induced cytokine production and cell death: investigating the potential roles of the p38, p53, and NF- κ B signaling pathways with RNA interference,” *Journal of Biochemical and Molecular Toxicology*, vol. 24, no. 3, pp. 155–164, 2010.
- [50] M. A. Cassatella, “The production of cytokines by polymorphonuclear neutrophils,” *Immunology Today*, vol. 16, no. 1, pp. 21–26, 1995.
- [51] A. El-Gamel, E. Sim, P. Hasleton et al., “Transforming growth factor β (TGF- β) and obliterative bronchiolitis following pulmonary transplantation,” *Journal of Heart and Lung Transplantation*, vol. 18, no. 9, pp. 828–837, 1999.
- [52] R. Aghanouri, M. Ghanei, J. Aslani, H. Keivani-Amine, F. Rastegar, and A. Karkhane, “Fibrogenic cytokine levels in bronchoalveolar lavage aspirates 15 years after exposure to sulfur mustard,” *American Journal of Physiology*, vol. 287, pp. L1160–L1164, 2004.
- [53] M. Ghanei, Y. Panahi, M. Mojtahedzadeh, A. R. Hosseini Khalili, and J. Aslani, “Effect of gamma interferon on lung function of mustard gas exposed patients, after 15 years,” *Pulmonary Pharmacology and Therapeutics*, vol. 19, no. 2, pp. 148–153, 2006.
- [54] S. Pourfarzam, T. Ghazanfari, R. Yaraee et al., “Serum levels of IL-8 and IL-6 in the long term pulmonary complications induced by sulfur mustard: sardasht-Iran Cohort Study,” *International Immunopharmacology*, vol. 9, no. 13-14, pp. 1482–1488, 2009.
- [55] H. Ghasemi, T. Ghazanfari, R. Yaraee et al., “Evaluation of relationship between the serum levels of inflammatory mediators and ocular injuries induced by sulfur mustard: sardasht-Iran Cohort Study,” *International Immunopharmacology*, vol. 9, no. 13-14, pp. 1494–1498, 2009.